Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Jul 15;98(2):556–562. doi: 10.1172/JCI118823

Functional beta3-adrenoceptor in the human heart.

C Gauthier 1, G Tavernier 1, F Charpentier 1, D Langin 1, H Le Marec 1
PMCID: PMC507461  PMID: 8755668

Abstract

Beta3-adrenoceptors are involved in metabolism, gut relaxation, and vascular vasodilation. However, their existence and role in the human heart have not been documented. We investigated the effects of several beta-adrenoceptor agonists and antagonists on the mechanical properties of ventricular endomyocardial biopsies. In the presence of nadolol, a beta1- and beta2-adrenoceptor antagonist, isoprenaline produced consistent negative inotropic effects. Similar negative inotropic effects also resulted from the action of beta3-adrenoceptor agonists with an order of potency: BRL 37344 > SR 58611 approximately CL 316243 > CGP 12177. The dose-response curve to BRL 37344-decreasing myocardial contractility was not modified by pretreatment with nadolol, but was shifted to the right by bupranolol, a nonselective beta-adrenoceptor antagonist. Beta3-adrenoceptor agonists also induced a reduction in the amplitude and an acceleration in the repolarization phase of the human action potential. Beta3-adrenoceptor transcripts were detected in human ventricle by a polymerase chain reaction assay. These results indicate that: (a) beta3-adrenoceptors are present and functional in the human heart; and (b) these receptors are responsible for the unexpected negative inotropic effects of catecholamines and may be involved in pathophysiological mechanisms leading to heart failure.

Full Text

The Full Text of this article is available as a PDF (238.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arch J. R., Ainsworth A. T., Cawthorne M. A., Piercy V., Sennitt M. V., Thody V. E., Wilson C., Wilson S. Atypical beta-adrenoceptor on brown adipocytes as target for anti-obesity drugs. Nature. 1984 May 10;309(5964):163–165. doi: 10.1038/309163a0. [DOI] [PubMed] [Google Scholar]
  2. Berkowitz D. E., Nardone N. A., Smiley R. M., Price D. T., Kreutter D. K., Fremeau R. T., Schwinn D. A. Distribution of beta 3-adrenoceptor mRNA in human tissues. Eur J Pharmacol. 1995 Apr 28;289(2):223–228. doi: 10.1016/0922-4106(95)90098-5. [DOI] [PubMed] [Google Scholar]
  3. Berlan M., Galitzky J., Bousquet-Melou A., Lafontan M., Montastruc J. L. Beta-3 adrenoceptor-mediated increase in cutaneous blood flow in the dog. J Pharmacol Exp Ther. 1994 Mar;268(3):1444–1451. [PubMed] [Google Scholar]
  4. Bond R. A., Clarke D. E. Agonist and antagonist characterization of a putative adrenoceptor with distinct pharmacological properties from the alpha- and beta-subtypes. Br J Pharmacol. 1988 Nov;95(3):723–734. doi: 10.1111/j.1476-5381.1988.tb11698.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brodde O. E. Beta 1- and beta 2-adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev. 1991 Jun;43(2):203–242. [PubMed] [Google Scholar]
  6. Brodde O. E. Beta-adrenoceptors in cardiac disease. Pharmacol Ther. 1993 Dec;60(3):405–430. doi: 10.1016/0163-7258(93)90030-h. [DOI] [PubMed] [Google Scholar]
  7. Bylund D. B., Eikenberg D. C., Hieble J. P., Langer S. Z., Lefkowitz R. J., Minneman K. P., Molinoff P. B., Ruffolo R. R., Jr, Trendelenburg U. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev. 1994 Jun;46(2):121–136. [PubMed] [Google Scholar]
  8. Bégin-Heick N. Beta 3-adrenergic activation of adenylyl cyclase in mouse white adipocytes: modulation by GTP and effect of obesity. J Cell Biochem. 1995 Aug;58(4):464–473. doi: 10.1002/jcb.240580409. [DOI] [PubMed] [Google Scholar]
  9. Chaudhry A., MacKenzie R. G., Georgic L. M., Granneman J. G. Differential interaction of beta 1- and beta 3-adrenergic receptors with Gi in rat adipocytes. Cell Signal. 1994 May;6(4):457–465. doi: 10.1016/0898-6568(94)90093-0. [DOI] [PubMed] [Google Scholar]
  10. Dolan J. A., Muenkel H. A., Burns M. G., Pellegrino S. M., Fraser C. M., Pietri F., Strosberg A. D., Largis E. E., Dutia M. D., Bloom J. D. Beta-3 adrenoceptor selectivity of the dioxolane dicarboxylate phenethanolamines. J Pharmacol Exp Ther. 1994 Jun;269(3):1000–1006. [PubMed] [Google Scholar]
  11. Emorine L. J., Marullo S., Briend-Sutren M. M., Patey G., Tate K., Delavier-Klutchko C., Strosberg A. D. Molecular characterization of the human beta 3-adrenergic receptor. Science. 1989 Sep 8;245(4922):1118–1121. doi: 10.1126/science.2570461. [DOI] [PubMed] [Google Scholar]
  12. Galitzky J., Reverte M., Carpene C., Lafontan M., Berlan M. Beta 3-adrenoceptors in dog adipose tissue: studies on their involvement in the lipomobilizing effect of catecholamines. J Pharmacol Exp Ther. 1993 Jul;266(1):358–366. [PubMed] [Google Scholar]
  13. Gauthier C., Laurent K., Charpentier F., Drouin E., Chevallier J. C., Le Marec H. Endomyocardial biopsies: a new approach for studying the electrical and mechanical properties of human ventricular myocardium. J Mol Cell Cardiol. 1994 Oct;26(10):1267–1271. doi: 10.1006/jmcc.1994.1146. [DOI] [PubMed] [Google Scholar]
  14. Granneman J. G., Lahners K. N., Chaudhry A. Characterization of the human beta 3-adrenergic receptor gene. Mol Pharmacol. 1993 Aug;44(2):264–270. [PubMed] [Google Scholar]
  15. Jones C. R., Molenaar P., Summers R. J. New views of human cardiac beta-adrenoceptors. J Mol Cell Cardiol. 1989 May;21(5):519–535. doi: 10.1016/0022-2828(89)90791-8. [DOI] [PubMed] [Google Scholar]
  16. Kaumann A. J., Hall J. A., Murray K. J., Wells F. C., Brown M. J. A comparison of the effects of adrenaline and noradrenaline on human heart: the role of beta 1- and beta 2-adrenoceptors in the stimulation of adenylate cyclase and contractile force. Eur Heart J. 1989 Jun;10 (Suppl B):29–37. doi: 10.1093/eurheartj/10.suppl_b.29. [DOI] [PubMed] [Google Scholar]
  17. Kaumann A. J. Is there a third heart beta-adrenoceptor? Trends Pharmacol Sci. 1989 Aug;10(8):316–320. doi: 10.1016/0165-6147(89)90065-5. [DOI] [PubMed] [Google Scholar]
  18. Kaumann A. J., Lobnig B. M. Mode of action of (-)-pindolol on feline and human myocardium. Br J Pharmacol. 1986 Sep;89(1):207–218. doi: 10.1111/j.1476-5381.1986.tb11137.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Koike K., Takayanagi I., Muramatsu M., Ohki S., Horinouchi T. Involvement of beta 3-adrenoceptor in the relaxation response in guinea pig taenia caecum. Jpn J Pharmacol. 1994 Oct;66(2):213–220. doi: 10.1254/jjp.66.213. [DOI] [PubMed] [Google Scholar]
  20. Krief S., Lönnqvist F., Raimbault S., Baude B., Van Spronsen A., Arner P., Strosberg A. D., Ricquier D., Emorine L. J. Tissue distribution of beta 3-adrenergic receptor mRNA in man. J Clin Invest. 1993 Jan;91(1):344–349. doi: 10.1172/JCI116191. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Langin D., Laurell H., Holst L. S., Belfrage P., Holm C. Gene organization and primary structure of human hormone-sensitive lipase: possible significance of a sequence homology with a lipase of Moraxella TA144, an antarctic bacterium. Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4897–4901. doi: 10.1073/pnas.90.11.4897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Langin D., Portillo M. P., Saulnier-Blache J. S., Lafontan M. Coexistence of three beta-adrenoceptor subtypes in white fat cells of various mammalian species. Eur J Pharmacol. 1991 Jul 9;199(3):291–301. doi: 10.1016/0014-2999(91)90492-9. [DOI] [PubMed] [Google Scholar]
  23. Lee R. J., Evans D. B., Baky S. H., Laffan R. J. Pharmacology of nadolol (SQ 11725), a beta-adrenergic antagonist lacking direct myocardial depression. Eur J Pharmacol. 1975 Sep-Oct;33(2):371–382. doi: 10.1016/0014-2999(75)90182-x. [DOI] [PubMed] [Google Scholar]
  24. Lowell B. B., Flier J. S. The potential significance of beta 3 adrenergic receptors. J Clin Invest. 1995 Mar;95(3):923–923. doi: 10.1172/JCI117798. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Lönnqvist F., Krief S., Strosberg A. D., Nyberg S., Emorine L. J., Arner P. Evidence for a functional beta 3-adrenoceptor in man. Br J Pharmacol. 1993 Nov;110(3):929–936. doi: 10.1111/j.1476-5381.1993.tb13902.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Manara L., Bianchetti A. Further heterogeneity of the beta-adrenoceptor. The phenylethanolaminotetralines: new selective agonists for atypical beta-adrenoceptors. Trends Pharmacol Sci. 1990 Jun;11(6):229–230. doi: 10.1016/0165-6147(90)90247-6. [DOI] [PubMed] [Google Scholar]
  27. Martin C. A., Advenier C. Beta 3-adrenoceptors and airways. Fundam Clin Pharmacol. 1995;9(2):114–118. doi: 10.1111/j.1472-8206.1995.tb00270.x. [DOI] [PubMed] [Google Scholar]
  28. Pietri-Rouxel F., Strosberg A. D. Pharmacological characteristics and species-related variations of beta 3-adrenergic receptors. Fundam Clin Pharmacol. 1995;9(3):211–218. doi: 10.1111/j.1472-8206.1995.tb00288.x. [DOI] [PubMed] [Google Scholar]
  29. Shen Y. T., Zhang H., Vatner S. F. Peripheral vascular effects of beta-3 adrenergic receptor stimulation in conscious dogs. J Pharmacol Exp Ther. 1994 Jan;268(1):466–473. [PubMed] [Google Scholar]
  30. Strosberg A. D. Structure, function, and regulation of adrenergic receptors. Protein Sci. 1993 Aug;2(8):1198–1209. doi: 10.1002/pro.5560020802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Sugasawa T., Matsuzaki M., Morooka S., Foignant N., Blin N., Strosberg A. D. In vitro study of a novel atypical beta-adrenoceptor agonist, SM-11044. Eur J Pharmacol. 1992 Jun 5;216(2):207–215. doi: 10.1016/0014-2999(92)90362-8. [DOI] [PubMed] [Google Scholar]
  32. Takayama S., Furukawa Y., Ren L. M., Inoue Y., Sawaki S., Chiba S. Positive chronotropic and inotropic responses to BRL 37344, a beta 3-adrenoceptor agonist in isolated, blood-perfused dog atria. Eur J Pharmacol. 1993 Feb 16;231(3):315–321. doi: 10.1016/0014-2999(93)90105-q. [DOI] [PubMed] [Google Scholar]
  33. Tavernier G., Galitzky J., Bousquet-Melou A., Montastruc J. L., Berlan M. The positive chronotropic effect induced by BRL 37344 and CGP 12177, two beta-3 adrenergic agonists, does not involve cardiac beta adrenoceptors but baroreflex mechanisms. J Pharmacol Exp Ther. 1992 Dec;263(3):1083–1090. [PubMed] [Google Scholar]
  34. Wheeldon N. M., McDevitt D. G., Lipworth B. J. Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man. Br J Clin Pharmacol. 1994 Apr;37(4):363–369. doi: 10.1111/j.1365-2125.1994.tb04290.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wheeldon N. M., McDevitt D. G., Lipworth B. J. Investigation of putative cardiac beta 3-adrenoceptors in man. Q J Med. 1993 Apr;86(4):255–261. [PubMed] [Google Scholar]
  36. Xiao R. P., Ji X., Lakatta E. G. Functional coupling of the beta 2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol. 1995 Feb;47(2):322–329. [PubMed] [Google Scholar]
  37. Zaagsma J., Nahorski S. R. Is the adipocyte beta-adrenoceptor a prototype for the recently cloned atypical 'beta 3-adrenoceptor'? Trends Pharmacol Sci. 1990 Jan;11(1):3–7. doi: 10.1016/0165-6147(90)90032-4. [DOI] [PubMed] [Google Scholar]
  38. del Monte F., Kaumann A. J., Poole-Wilson P. A., Wynne D. G., Pepper J., Harding S. E. Coexistence of functioning beta 1- and beta 2-adrenoceptors in single myocytes from human ventricle. Circulation. 1993 Sep;88(3):854–863. doi: 10.1161/01.cir.88.3.854. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES